首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1898178

精準免疫腫瘤市場規模、佔有率和成長分析（按癌症類型、治療方法、生物標記、最終用途和地區分類）—產業預測（2026-2033 年）

Precision Immuno-Oncology Market Size, Share, and Growth Analysis, By Cancer Type (Lung Cancer, Breast Cancer), By Treatment Type (Checkpoint Inhibitors, Car T Cell Therapy), By Biomarker, By End Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球精準免疫腫瘤學市場預計到 2024 年將達到 672 億美元，到 2025 年將達到 744.6 億美元，到 2033 年將達到 1,691.3 億美元，預測期（2026-2033 年）的複合年成長率為 10.8%。

精準免疫腫瘤學作為一種革命性的癌症治療方法，正迅速崛起，其核心在於根據患者的基因譜、腫瘤特徵和免疫反應量身定做個人化治療方案。這種創新策略不僅能提高治療效果，促進長期緩解，而且與傳統療法相比，還能顯著降低副作用。借助先進的診斷工具，醫生可以識別癌細胞內的特定基因突變和獨特標誌物，從而實現精準標靶治療治療，為患者提供個人化治療。精準免疫腫瘤學能夠在改善患者預後的同時保護健康組織，其優勢凸顯，並在製藥業催生了一個蓬勃發展的市場。該領域不斷成長的投資和研究也表明，人們通用認為精準免疫腫瘤學能夠重塑癌症治療模式。

全球精準免疫腫瘤市場促進因素

全球癌症發生率的不斷攀升仍然是一項重大的公共衛生挑戰，也因此推動了更有效治療方法的需求。傳統的治療方法，例如化療和放射線治療，有許多局限性，並可能為患者帶來嚴重的副作用。相較之下，精準免疫腫瘤學是一種突破性的策略，它利用個體自身免疫系統的力量來更有效地攻擊癌細胞。隨著對先進的個人化治療方法的需求日益成長，精準免疫腫瘤學已成為市場的重要驅動力，它有望根據患者的基因譜和腫瘤特徵量身定做治療方案，最終在改善治療效果的同時，最大限度地減少傳統療法帶來的不良副作用。

限制全球精準免疫腫瘤市場發展的因素

精準免疫腫瘤學市場面臨的一大挑戰是這些創新療法的高昂成本。與傳統癌症治療不同，精準免疫腫瘤學需要個人化治療方案和複雜的調查方法，這會導致高昂的費用。這種經濟負擔會限制患者獲得治療的機會，尤其是在醫療資源有限的發展中地區。導致成本上升的因素有很多，包括大規模的研發投入、對先進醫療設備的需求以及用於篩選合格患者的生物標記檢測。因此，高昂的治療費用會導致治療機會的不平等，尤其是在中低收入患者群體中，並阻礙公平的癌症治療和治療效果。

全球精準免疫腫瘤市場趨勢

全球精準免疫腫瘤市場正呈現顯著的聯合治療趨勢，將免疫療法與化療、放射線治療等傳統療法結合。這種多管齊下的治療方法充分發揮每種治療方法的優勢，不僅能縮小腫瘤，還能活化患者自身的免疫系統，有效標靶並清除癌細胞，進而提高治療效果。隨著對單一治療方法的抗藥性日益凸顯，聯合治療策略的應用正受到越來越多的關注，使腫瘤學家能夠繞過適應性抗藥性機制，並透過多種生物學途徑擴大對癌症的治療範圍。這項發展有望重新定義癌症治療，並顯著改善患者的預後。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Adaptimmune Therapeutics plc（UK）
Agenus Inc.（US）
Amgen Inc.（US）
AstraZeneca plc（UK）
Bristol Myers Squibb Company（US）
Celgene Corporation（US）
Eli Lilly and Company（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
Gilead Sciences, Inc.（US）
GlaxoSmithKline plc（UK）
Iovance Biotherapeutics, Inc.（US）
Juno Therapeutics, Inc.（US）
Kite Pharma, Inc.（US）
Merck & Co., Inc.（US）
Neon Therapeutics, Inc.（US）
Novartis AG（Switzerland）
Pfizer Inc.（US）
Sanofi SA（France）
Seattle Genetics, Inc.（US）
Takeda Pharmaceutical Company Limited（Japan）

結論與建議

簡介目錄

Product Code: SQMIG35H2063

Global Precision Immuno-Oncology Market size was valued at USD 67.2 Billion in 2024 and is poised to grow from USD 74.46 Billion in 2025 to USD 169.13 Billion by 2033, growing at a CAGR of 10.8% during the forecast period (2026-2033).

Precision immuno-oncology is rapidly gaining traction as a transformative approach in cancer treatment, focusing on individualized therapies tailored to patients' genetic profiles, tumor characteristics, and immune responses. This innovative strategy not only enhances treatment efficacy and fosters long-term remissions but also significantly minimizes side effects compared to traditional methods. Utilizing advanced diagnostic tools, physicians can identify specific genetic mutations and unique markers within cancer cells, allowing for precise targeting by tailored therapies. The potential to improve patient outcomes while preserving healthy tissue underscores its appeal, leading to a burgeoning market within the pharmaceutical sector. Increasing investments and research in this domain highlight a collective recognition of precision immuno-oncology's capacity to redefine the landscape of cancer care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Precision Immuno-Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Precision Immuno-Oncology Market Segments Analysis

Global Precision Immuno-Oncology Market is segmented by cancer type, treatment type, biomarker, end use and region. Based on cancer type, the market is segmented into lung cancer, breast cancer, prostate cancer, melanoma and others. Based on treatment type, the market is segmented into checkpoint inhibitors, Car T Cell Therapy, cancer vaccines and others. Based on biomarker, the market is segmented into PD-L1, BRCA, KRAS, EGFR and others. Based on end use, the market is segmented into hospital, clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Precision Immuno-Oncology Market

The global rise in cancer incidence remains a significant public health challenge, leading to an increased demand for more effective treatment options. Traditional therapies, such as chemotherapy and radiation, often come with considerable limitations and can impose severe side effects on patients. In contrast, precision immuno-oncology represents a groundbreaking strategy that harnesses the power of an individual's immune system to combat cancer more effectively. As the need for advanced and tailored therapies rises, precision immuno-oncology stands out as a pivotal force in the market, promising personalized treatments that align with a patient's genetic profile and tumor characteristics, ultimately enhancing outcomes while minimizing adverse effects associated with conventional methods.

Restraints in the Global Precision Immuno-Oncology Market

A significant challenge in the precision immuno-oncology market is the high cost associated with these innovative therapies. Unlike traditional cancer treatments, precision immuno-oncology involves a personalized approach and complex methodologies, making it often more expensive. This financial burden can restrict patient access, particularly for those in developing regions with limited healthcare resources. Various elements contribute to the elevated costs, including extensive research and development investments, the need for advanced medical equipment, and the utilization of biomarker testing to select appropriate candidates for treatment. Consequently, the high price tag can lead to disparities in treatment availability, especially among low- and middle-income populations, ultimately hindering equitable cancer care and outcomes.

Market Trends of the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market is experiencing a notable trend towards combination therapies that integrate immunotherapy with traditional treatments like chemotherapy and radiation. This multifaceted approach enhances treatment efficacy, leveraging the strengths of each modality to not only shrink tumors but also empower the patient's immune system to effectively target and eliminate cancer cells. As resistance to individual therapies becomes a significant challenge, the use of combinatorial strategies is gaining traction, enabling oncologists to circumvent adaptive resistance mechanisms and broaden the therapeutic attack on cancer through various biological pathways. This evolution is poised to redefine cancer care and improve patient outcomes significantly.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Pipeline Product Analysis
Case Study Analysis

Global Precision Immuno-Oncology Market Size by Cancer Type & CAGR (2026-2033)

Market Overview
Lung Cancer
Breast Cancer
Prostate Cancer
Melanoma
Others

Global Precision Immuno-Oncology Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Checkpoint Inhibitors
Car T Cell Therapy
Cancer Vaccines
Others

Global Precision Immuno-Oncology Market Size by Biomarker & CAGR (2026-2033)

Market Overview
PD-L1
BRCA
KRAS
EGFR
Others

Global Precision Immuno-Oncology Market Size by End Use & CAGR (2026-2033)

Market Overview
Hospital
Clinics
Research Institutes
Others

Global Precision Immuno-Oncology Market Size & CAGR (2026-2033)

North America (Cancer Type, Treatment Type, Biomarker, End Use)
- US
- Canada
Europe (Cancer Type, Treatment Type, Biomarker, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Cancer Type, Treatment Type, Biomarker, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Cancer Type, Treatment Type, Biomarker, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Cancer Type, Treatment Type, Biomarker, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Adaptimmune Therapeutics plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agenus Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Iovance Biotherapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Juno Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kite Pharma, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neon Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seattle Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments